Details of the Drug

General Information of Drug (ID: DMZMSPF)

• Drug Name: Bicalutamide
• Synonyms: Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]
Castration-resistant prostate carcinoma	N.A.	Investigative	[2]
Metastatic prostate carcinoma	N.A.	Investigative	[2]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L02BB03: Bicalutamide
  L02BB: Anti-androgens
  L02B: HORMONE ANTAGONISTS AND RELATED AGENTS
  L02: ENDOCRINE THERAPY
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 430.4
  Logarithm of the Partition Coefficient (xlogp); 2.3
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 9
• ADMET Property:
  Absorption: The drug is well-absorbed following oral administration []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
  Clearance: The apparent oral clearance of drug is 0.32 L/h []
  Half-life: The concentration or amount of drug in body reduced by one-half in 5.9 days [4]
  Metabolism: The drug is metabolized via the glucuronidation []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.93549 micromolar/kg/day [5]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.005 mg/mL [3]
• Chemical Identifiers:
  Formula: C18H14F4N2O4S
  IUPAC Name: N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
  Canonical SMILES: CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
  InChI: InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
  InChIKey: LKJPYSCBVHEWIU-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2375
  ChEBI ID: CHEBI:91617
  CAS Number: 90357-06-5
  UNII: A0Z3NAU9DP
  DrugBank ID: DB01128
  TTD ID: D0V9BD
  VARIDT ID: DR00795
  INTEDE ID: DR0210
  ACDINA ID: D00069
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Antagonist	[6]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[7]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
26S proteasome complex subunit SEM1 (SEM1)	OTASLBM1	SEM1_HUMAN	Gene/Protein Processing	[9]
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase (EBP)	OTSMGKXQ	EBP_HUMAN	Gene/Protein Processing	[10]
Aldehyde dehydrogenase family 3 member A2 (ALDH3A2)	OT714BUO	AL3A2_HUMAN	Gene/Protein Processing	[10]
Alpha-methylacyl-CoA racemase (AMACR)	OTUU22PK	AMACR_HUMAN	Gene/Protein Processing	[10]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Gene/Protein Processing	[10]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Drug Response	[11]
Angio-associated migratory cell protein (AAMP)	OTZXBSS4	AAMP_HUMAN	Gene/Protein Processing	[9]
Ankyrin repeat and IBR domain-containing protein 1 (ANKIB1)	OTGKB7Y2	AKIB1_HUMAN	Gene/Protein Processing	[9]
Anterior gradient protein 2 homolog (AGR2)	OTRRZT7W	AGR2_HUMAN	Gene/Protein Processing	[10]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[12]

Molecular Expression Atlas of This Drug

• The Studied Disease: Prostate cancer
• ICD Disease Classification: 2C82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11
P-glycoprotein 1 (ABCB1)	DTP	P-GP	2.80E-02	-1.36E-01	-1.05E+00
Breast cancer resistance protein (ABCG2)	DTP	BCRP	1.91E-02	2.50E-01	1.01E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	7.93E-02	-8.20E-02	-8.93E-01

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC1	6.1707	8.3999	2.5885	0.5265
NOS-1 [Human HNSCC]	GDSC1	1.1909	5.0588	0.3679	22.8613
MG-63	GDSC1	2.2783	3.803	-0.4603	0.3353
TC-71	GDSC1	3.9443	6.8285	2.0564	5.6261
HOS	GDSC1	4.3461	7.0193	2.2413	3.8614
CAL-72	GDSC1	4.4827	7.8868	1.9193	5.3088
CHSA8926	GDSC1	4.6312	8.3906	1.7782	5.7808
ES1	GDSC1	4.7709	6.6941	2.6354	1.3556
U2OS	GDSC1; GDSC2	4.809	7.2394	2.4197	2.27
EW-12	GDSC2	4.809	7.1101	2.4765	2.2753
EW-24	GDSC1	4.824	6.7531	2.6374	1.2921
U-CH2	GDSC2	4.8576	7.2399	2.4463	2.3627
A-673	GDSC1	4.8777	7.3673	2.4014	2.2665
SK-PN-DW	GDSC1	4.8994	9.0036	1.6636	5.8991
ES4	GDSC1	4.9013	7.8888	2.1818	3.2793
SaOS-2	GDSC1	4.9102	9.1593	1.597	6.2237
CHSA0011	GDSC1; GDSC2	4.9744	7.6709	2.3212	2.5139
EW-11	GDSC1	5.0408	12.4203	0.1135	13.3611
EW-3	GDSC1	5.0888	7.9481	2.2625	2.6385
EW-7	GDSC1	5.1046	7.1018	2.6301	1.0599
CADO-ES1	GDSC1	5.1213	6.7765	2.766	0.8267
ES5	GDSC1; GDSC2	5.2066	8.4505	2.1058	3.2167
CHSA0108	GDSC1; GDSC2	5.2236	7.9514	2.334	2.1521
MHH-ES-1	GDSC1; GDSC2	5.3174	7.6901	2.4915	1.3998
HuO-3N1	GDSC1	5.3217	8.5474	2.1274	2.964
EW-13	GDSC1	5.4351	7.2306	2.7253	0.5257
SJSA-1	GDSC1	5.4412	7.5912	2.5891	0.941
SK-ES-1	GDSC1	5.5023	7.4663	2.6642	0.6623
EW-18	GDSC1	5.5812	8.1506	2.4296	1.4014
G-292 clone A141B1	GDSC1	5.5903	8.0356	2.4803	1.2071
HuO9	GDSC1	5.5945	8.3305	2.3623	1.6486
CAL-78	GDSC1	5.8156	7.7641	2.681	0.4584
ES6	GDSC1	5.8463	8.1682	2.542	0.8218
ES7	GDSC1	5.8865	8.5792	2.3991	1.2629
EW-16	GDSC1	5.9169	8.1291	2.5865	0.6531
EW-22	GDSC1	5.9431	8.8917	2.2998	2.2186
ES8	GDSC1	5.9519	8.0518	2.6295	0.5237
H-EMC-SS	GDSC1	6.1174	8.3966	2.5684	0.6007
NY	GDSC1	6.1563	8.5179	2.5391	0.6581
EW-1	GDSC1	6.5575	8.7361	2.6159	0.3298

Cancer Drug Sensitivity Data Curated from 167 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JM1	GDSC1; GDSC2	4.9659	6.9121	2.6413	1.1396
SCC-3	GDSC1	1.4364	2.6553	-0.372	0.5326
WIL2 NS	GDSC1	1.8083	3.2645	-0.4476	0.551
SUP-B15	GDSC1	1.8396	3.4492	-0.504	0.7474
Granta-519	GDSC1	1.9194	3.7605	-0.5896	1.0495
KMS-12-BM	GDSC1	1.9966	3.4249	-0.432	0.3875
SK-MM-2	GDSC1	2.1964	4.2134	-0.6446	1.0397
VAL	GDSC1	2.5883	4.9282	-0.7513	1.1571
SU-DHL-5	GDSC1	3.6793	5.7248	2.4038	4.2842
A3/Kawakami	GDSC1	3.8716	6.3919	2.2175	4.8974
DB	GDSC1	3.8878	7.2477	1.8083	7.1085
BC-1	GDSC1	3.9381	6.7784	2.0764	5.5299
MOLT-13	GDSC1	4.0163	7.1924	1.9304	8.6571
NOMO-1	GDSC1	4.0277	10.5205	0.2926	14.7575
RC-K8	GDSC1	4.0337	6.1378	2.4539	3.3003
MOLT-16	GDSC1	4.0864	6.3081	2.4078	3.4481
L-540	GDSC1	4.178	6.5262	2.3647	3.5105
SR	GDSC1	4.1786	13.7881	-1.2155	20.9079
WSU-DLCL2	GDSC1	4.1854	5.9729	2.6282	2.1412
JeKo-1	GDSC1; GDSC2	4.1965	9.8793	0.7405	13.5816
NU-DUL-1	GDSC1; GDSC2	4.1989	8.5253	1.41	8.5998
Kasumi-1	GDSC1; GDSC2	4.2036	7.0507	2.1313	5.3247
L-363	GDSC1	4.2479	5.9259	2.6866	1.7621
SU-DHL-10	GDSC1	4.3018	5.9006	2.7286	2.1029
EoL-1	GDSC1	4.3043	7.0741	2.1878	4.216
DoHH2	GDSC1; GDSC2	4.3268	8.6215	1.4558	8.0851
OCI-Ly7	GDSC2	4.3375	5.8387	2.7751	1.3981
ATN-1	GDSC1	4.373	7.6035	1.9811	5.1848
NK-92MI	GDSC1; GDSC2	4.3818	7.3725	2.0972	4.5541
Reh	GDSC1	4.3846	7.2574	2.1537	4.2518
CML-T1	GDSC1	4.3913	7.6562	1.9682	7.3271
SU-DHL-4	GDSC1; GDSC2	4.4268	8.7183	1.4799	7.7526
SKM-1	GDSC1; GDSC2	4.43	7.3051	2.1607	4.6828
RPMI-8402	GDSC1	4.4518	7.3227	2.1666	4.0675
DG-75	GDSC1	4.4615	7.5684	2.0568	4.6237
NB4	GDSC1; GDSC2	4.4639	6.268	2.6565	1.6166
CMK	GDSC1	4.4698	9.5541	1.1029	13.206
IM-9	GDSC1	4.4737	6.5802	2.5231	2.2333
RCH-ACV	GDSC1; GDSC2	4.4739	7.4137	2.138	4.7305
TALL-1 [Human adult T-ALL]	GDSC2	4.4764	7.6351	2.0349	5.3336
Karpas-299	GDSC1	4.4859	6.82	2.4214	2.7142
HH [Human lymphoma]	GDSC1	4.49	7.3582	2.1744	3.9619
SU-DHL-16	GDSC1; GDSC2	4.4935	6.712	2.4751	2.4384
KG-1	GDSC1	4.497	6.7627	2.4542	2.5359
HAL-01	GDSC1	4.5123	6.864	2.4171	2.6958
GDM-1	GDSC1	4.5163	7.2405	2.246	3.5502
KMOE-2	GDSC1	4.5169	7.9315	1.9208	5.2389
MV4-11	GDSC1	4.5196	7.2121	2.2613	3.467
ME1	GDSC1	4.5394	6.1066	2.7656	1.0535
TUR	GDSC1	4.5465	7.2674	2.2524	3.4691
Karpas-620	GDSC1	4.5609	6.9617	2.4016	2.7002
OCI-AML-5	GDSC1	4.5793	6.0834	2.7949	0.8967
MHH-CALL-2	GDSC1	4.5886	6.6039	2.5776	2.57
MOLT-4	GDSC1	4.5925	6.7184	2.5292	2.0416
SUP-M2	GDSC1	4.5975	5.6576	2.9706	0.2936
MC116	GDSC1; GDSC2	4.5995	5.773	2.9278	0.414
SUP-B8	GDSC1; GDSC2	4.6037	7.6266	2.121	4.581
Farage	GDSC1; GDSC2	4.6223	7.4056	2.2352	3.4355
SU-DHL-1	GDSC1; GDSC2	4.6249	12.426	-0.1951	15.6633
ALL-SIL	GDSC1	4.6394	6.6196	2.5984	1.6646
DEL	GDSC1	4.6508	5.9896	2.8661	0.5776
BE-13	GDSC1	4.6516	7.5172	2.2016	3.5585
RPMI-8866	GDSC1	4.6532	6.7734	2.5387	1.9191
KE-37	GDSC1	4.6593	5.9739	2.876	0.5386
JVM-3	GDSC1	4.6623	7.217	2.3456	2.8263
MHH-PREB-1	GDSC1	4.6649	8.6908	1.6574	6.3525
SIG-M5	GDSC1; GDSC2	4.6664	5.9074	2.9049	0.4427
BALL-1	GDSC1	4.6742	8.1782	1.9071	5.0313
AMO1	GDSC1	4.6803	6.7327	2.5713	1.7371
H9	GDSC1	4.6941	7.0596	2.4349	2.3509
HT	GDSC1; GDSC2	4.6978	8.7778	1.6379	6.3942
Karpas-422	GDSC1	4.7126	6.4789	2.6965	1.1623
U-698-M	GDSC1	4.7142	7.7059	2.1529	3.7054
OCI-AML-2	GDSC1	4.7288	6.1529	2.8367	0.6204
THP-1	GDSC1; GDSC2	4.7492	6.6704	2.6343	1.3831
LAMA-84	GDSC1	4.75	8.0446	2.0181	4.3315
RL	GDSC1; GDSC2	4.7644	9.8093	1.1875	8.6177
SU-DHL-8	GDSC1	4.7941	10.2378	1.0008	9.5209
LP-1	GDSC1; GDSC2	4.8003	6.563	2.7047	1.0449
BL-41	GDSC1	4.8096	6.3084	2.8116	0.6466
Jurkat	GDSC1	4.8107	8.4888	1.8488	7.1314
YT	GDSC1	4.811	6.8451	2.5919	1.4966
Sc-1	GDSC1	4.8234	6.5451	2.7232	0.9531
TK [Human B-cell lymphoma]	GDSC1	4.8239	6.5294	2.7298	0.9275
GR-ST	GDSC1	4.8584	7.7599	2.215	3.1795
Ku812	GDSC1	4.8604	7.3291	2.4087	2.2549
MOLM-13	GDSC1	4.8606	7.0803	2.5172	1.7653
697	GDSC1	4.8625	7.1502	2.488	1.8923
JURL-MK1	GDSC1	4.871	7.1733	2.4825	1.9064
MOLM-16	GDSC1; GDSC2	4.8923	6.5826	2.7403	0.9425
Jiyoye	GDSC1	4.8956	7.656	2.2833	2.7972
ARH-77	GDSC1	4.8998	8.5129	1.894	4.7186
CA46	GDSC1	4.9027	8.1495	2.0638	3.8591
HDLM-2	GDSC1	4.9059	7.3661	2.4174	2.1577
Ramos.2G6.4C10	GDSC1	4.9215	6.7766	2.6755	1.0479
EM-2	GDSC1	4.9314	6.5761	2.7607	0.7306
MHH-CALL-4	GDSC2	4.9504	10.5783	0.9449	10.6462
PL-21	GDSC1; GDSC2	4.9662	7.5799	2.3567	2.36
Mono-Mac-6	GDSC1	4.9677	12.3799	0.0805	13.6664
SUP-T1	GDSC1	4.974	7.4131	2.4338	2.0018
OCI-M1	GDSC1	4.9769	6.3823	2.855	0.4109
NCI-H929	GDSC1	4.9927	7.2407	2.5174	2.2807
U266B1	GDSC1	5.0115	6.9219	2.6591	1.0312
A4/Fukuda	GDSC1	5.0307	7.1122	2.5903	1.2794
CTB-1	GDSC1; GDSC2	5.045	9.1535	1.6865	5.5335
P12-Ichikawa	GDSC1	5.0464	6.246	2.932	0.2013
Raji	GDSC1	5.0545	6.7614	2.7428	0.7027
CRO-AP2	GDSC1; GDSC2	5.0768	6.8655	2.7118	0.8953
KM-H2	GDSC1	5.0899	7.2587	2.5587	1.3487
HL-60	GDSC1	5.0936	6.258	2.9454	0.1629
GA-10	GDSC1	5.1261	6.7422	2.7811	0.7588
ML-2	GDSC1	5.1313	6.9866	2.6885	0.8299
NKM-1	GDSC1	5.1434	9.5839	1.5476	6.0741
P32/ISH	GDSC1	5.147	6.663	2.8196	0.4193
VL51	GDSC1	5.1666	10.9125	0.9321	9.1471
MOLP-8	GDSC1	5.1688	6.9607	2.7153	0.714
BV-173	GDSC1	5.1753	7.9412	2.3127	2.3028
CCRF-CEM	GDSC1	5.188	6.966	2.7217	0.681
KMS-11	GDSC1; GDSC2	5.1898	7.7326	2.4099	2.1081
ALL-PO	GDSC1	5.1981	7.672	2.4399	1.726
RPMI-8226	GDSC1	5.2113	6.9683	2.7308	0.6376
Karpas-231	GDSC1	5.2139	6.6334	2.8571	0.2982
P31/FUJ	GDSC1	5.2189	6.7294	2.824	0.374
KOPN-8	GDSC1	5.2207	6.8298	2.7874	0.4682
HEL	GDSC1; GDSC2	5.2299	6.5486	2.8936	0.2168
WSU-NHL	GDSC1	5.245	7.1493	2.6753	0.7924
JVM-2	GDSC1	5.2536	7.8501	2.3929	1.8652
RPMI-6666	GDSC1	5.2545	7.1069	2.696	0.7188
Loucy	GDSC1	5.2549	6.857	2.7912	0.4406
OCI-AML-3	GDSC1	5.2644	6.6384	2.8746	0.2426
KY821	GDSC1	5.2803	6.878	2.7937	0.4218
CTV-1	GDSC1	5.2911	7.5064	2.554	1.1846
P30/OHK	GDSC1	5.2916	6.9727	2.763	0.4977
BC-3	GDSC1; GDSC2	5.296	7.6361	2.5034	1.3732
CESS	GDSC1	5.3266	7.2748	2.6623	0.7789
ST486	GDSC1	5.3684	6.7892	2.8602	0.2369
Daudi	GDSC1	5.3734	6.7513	2.8754	0.207
Karpas-45	GDSC1	5.4007	7.2653	2.6979	0.6225
OCI-Ly19	GDSC1; GDSC2	5.403	7.3099	2.6818	0.669
Hs 445	GDSC1	5.4105	6.9327	2.825	0.2939
NALM-6	GDSC1	5.4143	11.5085	0.8136	9.2752
QIMR-WIL	GDSC1; GDSC2	5.4189	8.7023	2.1129	2.9077
OPM-2	GDSC1	5.4377	7.2334	2.7253	0.5243
EB2	GDSC1	5.4702	7.4607	2.6527	0.7163
L-1236	GDSC1	5.4916	7.7807	2.5368	1.0838
JJN-3	GDSC1	5.4959	7.3967	2.688	0.597
Karpas-1106P	GDSC1	5.5411	7.3477	2.7248	0.669
K-562	GDSC1	5.5446	7.7704	2.5648	0.9485
LC4-1	GDSC1	5.5863	7.9406	2.5164	1.0828
PF-382	GDSC1	5.6136	7.457	2.7135	0.4689
Namalwa	GDSC1	5.6232	7.3484	2.757	0.3615
JSC-1	GDSC1	5.6264	7.5989	2.6659	0.5882
RS4;11	GDSC1	5.6667	7.7984	2.6071	0.7344
SUP-HD1	GDSC1	5.7017	7.7233	2.6502	0.5917
MLMA	GDSC1	5.7104	7.5753	2.7086	0.4378
SU-DHL-6	GDSC1	5.7511	7.4562	2.7672	0.2941
EHEB	GDSC1	5.7596	7.895	2.6095	0.6739
BONNA-12	GDSC2	5.7732	8.6712	2.3087	1.9164
MY-M12	GDSC1; GDSC2	5.8187	8.7501	2.2983	1.6915
L-428	GDSC1	5.8234	7.3351	2.836	0.1586
EJM	GDSC1	5.8267	7.5576	2.7597	0.2844
MEG-01	GDSC1	5.8269	8.0202	2.5902	0.6914
DND-41	GDSC1	5.8707	8.3163	2.4955	0.9512
HC-1	GDSC1	5.9159	7.5672	2.7892	0.2078
KCL-22	GDSC1	5.9641	7.8245	2.7165	0.324
MN-60	GDSC1	5.9699	7.6773	2.7706	0.2243
ROS-50	GDSC1; GDSC2	6.2422	11.1992	1.4685	4.804

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KYAE-1	GDSC1	4.491	7.2758	2.2136	5.2915
HCE-4	GDSC1; GDSC2	4.5078	6.4236	2.6123	1.7647
ESO-51	GDSC1	4.6771	7.2741	2.3284	4.0709
FLO-1	GDSC1	4.7855	8.1981	1.9689	6.3454
OACP4 C	GDSC1	5.3556	7.6654	2.52	1.7724
KYSE-50	GDSC1	5.4424	7.279	2.7101	0.5639
KYSE-220	GDSC1	5.6565	7.6677	2.6525	0.6093
ESO-26	GDSC1	5.9552	7.6263	2.7829	0.2936
OACM5.1 C	GDSC1	6.3545	8.7646	2.5276	0.837
TE-12	GDSC1; GDSC2	6.5542	9.1871	2.4516	0.6922
SK-GT-4	GDSC1	6.6196	8.7096	2.6479	0.3655

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC1	5.9717	8.0208	2.6487	0.4685

Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SK-N-AS	GDSC1	1.9088	3.5606	-0.5173	0.746
NB69	GDSC1	2.1078	4.4476	-0.7773	1.7742
CHP-212	GDSC1	2.1424	3.8026	-0.5123	0.5628
NH-12	GDSC1	2.1454	3.8236	-0.5189	0.5835
SJNB-6	GDSC1; GDSC2	3.6943	6.6093	1.9773	6.6111
SJNB-7	GDSC1	4.2338	7.5298	1.921	5.7727
SK-N-MC-IXC	GDSC1; GDSC2	4.2768	5.836	2.7432	1.4548
IMR-5	GDSC1	4.2952	8.4168	1.533	7.7367
SJNB-14	GDSC1	4.388	9.5528	1.0441	10.1348
GI-ME-N	GDSC1	4.4154	7.6178	2.0027	4.9915
SJNB-10	GDSC1	4.5303	6.5221	2.5813	1.8793
SJNB-5	GDSC1; GDSC2	4.6241	6.7344	2.5398	1.951
KP-N-RT-BM-1	GDSC2	4.6543	7.6929	2.1219	4.4817
MHH-NB-11	GDSC1; GDSC2	4.7261	7.0622	2.4518	2.2286
KP-N-YS	GDSC1; GDSC2	4.8251	6.9124	2.5706	1.5728
GOTO	GDSC1	4.8455	6.9122	2.5812	1.5048
SK-N-DZ	GDSC1	4.8675	6.5193	2.7542	0.8021
Kelly	GDSC1	4.9253	6.6909	2.7121	0.9076
SJNB-12	GDSC1	5.0114	8.3442	2.04	3.8123
CHP-126	GDSC1; GDSC2	5.0493	8.2001	2.1277	3.3298
SiMa	GDSC1	5.1492	7.1929	2.6142	1.0813
LA-N-6	GDSC1; GDSC2	5.2745	7.4748	2.559	1.1802
SK-N-FI	GDSC1	5.2945	7.1288	2.7049	0.6655
NB(TU)1	GDSC1	5.3526	7.0933	2.7429	0.521
TGW	GDSC1	5.6221	7.0589	2.8591	0.1694
SK-N-BE(2)-M17	GDSC1	5.6328	7.5712	2.6789	0.5496
SJNB-13	GDSC1	5.6783	7.3135	2.7906	0.2722
SJNB-17	GDSC2	5.8109	7.6047	2.7369	0.3796
KP-N-YN	GDSC1	5.8133	8.0755	2.5635	0.777
NB1	GDSC1	5.8157	7.201	2.8789	0.106
SK-N-SH	GDSC1	5.8737	7.8459	2.674	0.4503

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuCC-T1	GDSC1	5.4117	7.0152	2.7956	0.3587

Cancer Drug Sensitivity Data Curated from 52 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
UACC-812	GDSC1	1.9563	3.5743	-0.5028	0.6531
CAL-148	GDSC1	2.0705	3.2815	-0.3546	0.1692
AU565	GDSC1	2.1019	5.024	-1.0212	3.1776
ZR-75-30	GDSC1	2.3378	4.0721	-0.5339	0.519
MDA-MB-415	GDSC1	3.7467	5.3388	2.6418	2.8397
JIMT-1	GDSC1	4.0551	5.7903	2.6322	2.3298
BT-549	GDSC1	4.2706	6.9264	2.2358	4.0236
OCUB-M	GDSC1	4.317	6.4604	2.4841	2.6607
CAL-51	GDSC1	4.3839	6.5989	2.4611	2.6719
HCC2218	GDSC1; GDSC2	4.3959	7.4625	2.0637	4.7051
Hs 578T	GDSC1	4.5071	6.6942	2.4911	2.341
HCC1569	GDSC1; GDSC2	4.5532	7.8477	1.9845	4.8398
EFM-192A	GDSC1	4.6516	6.499	2.6568	1.3933
HCC1500	GDSC1	4.7097	6.8432	2.539	1.8471
T-47D	GDSC1	4.7566	8.3128	1.8968	4.9429
HCC70	GDSC1	4.7691	7.5523	2.2565	3.1065
CAL-120	GDSC1	4.869	8.492	1.8844	4.818
MFM-223	GDSC1	4.874	8.0153	2.1079	3.6835
MDA-MB-436	GDSC1	4.8889	7.4415	2.3749	2.3747
MCF-7	GDSC1	4.9511	6.9864	2.6033	1.3042
BT-474	GDSC1	4.9515	7.1231	2.5461	1.54
MDA-MB-330	GDSC1; GDSC2	4.9834	7.3441	2.4685	1.8379
HDQ-P1	GDSC1	5.0066	7.3605	2.4736	1.7895
HCC1187	GDSC1	5.0899	10.9258	0.8735	9.5866
HCC1395	GDSC1	5.0971	7.0194	2.6598	0.9572
MDA-MB-453	GDSC1	5.146	9.4231	1.6245	5.6803
HCC202	GDSC1	5.1499	7.6487	2.425	1.8403
EFM-19	GDSC1	5.213	7.7621	2.4094	1.8388
MRK-nu-1	GDSC1	5.2201	6.8714	2.7715	0.5125
HCC1599	GDSC1; GDSC2	5.228	9.1822	1.7868	4.7358
DU4475	GDSC1	5.2861	6.9334	2.7755	0.4668
YMB-1-E	GDSC2	5.2882	8.6353	2.0698	3.7082
COLO 824	GDSC1	5.2968	8.2994	2.2224	2.5616
CAL-85-1	GDSC1	5.3138	8.5867	2.1057	3.0749
MDA-MB-157	GDSC1	5.3288	7.6449	2.5156	1.2968
HCC1954	GDSC1	5.4451	10.1409	1.4775	5.9288
HCC1419	GDSC1	5.4527	7.7208	2.5429	1.0927
HCC1806	GDSC1	5.4666	7.4003	2.6742	0.6536
MDA-MB-468	GDSC1	5.4868	7.2113	2.7534	0.4275
HCC38	GDSC1	5.6098	7.6754	2.63	0.7002
HCC2157	GDSC1	5.6234	7.2291	2.7999	0.2718
BT-483	GDSC1	5.6243	7.4689	2.7134	0.4643
MDA-MB-231	GDSC1	5.6594	8.1033	2.485	1.1366
MDA-MB-361	GDSC1	5.7039	7.9455	2.5665	0.8354
HCC1428	GDSC1	5.7125	7.1534	2.8589	0.1498
Evsa-T	GDSC1	5.8019	7.1088	2.9051	0.0808
MDA-MB-175-VII	GDSC1	5.8104	7.3304	2.833	0.1657
HCC1937	GDSC1	5.8184	7.6449	2.7254	0.3567
UACC-893	GDSC1; GDSC2	6.0583	8.5992	2.4673	0.9189
HCC1143	GDSC1	6.1007	9.9557	1.9344	4.0465
BT-20	GDSC1	6.2294	7.7231	2.846	0.0831
CAMA-1	GDSC1	6.4552	18.6771	-1.927	18.6513

Cancer Drug Sensitivity Data Curated from 55 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PFSK-1	GDSC1	2.3646	4.4253	-0.6541	0.9382
SW1783	GDSC1	2.7469	4.7895	-0.635	0.6116
D-263MG	GDSC1	3.6042	5.3041	2.5551	3.6138
LN-18	GDSC1	4.0099	7.6499	1.7011	7.4288
D-542MG	GDSC1; GDSC2	4.1186	7.0203	2.0873	5.1034
GB-1	GDSC1	4.1732	7.4803	1.9024	5.994
LN-405	GDSC1	4.2802	6.3537	2.5107	2.5844
GaMG	GDSC1	4.4692	8.0266	1.8434	5.7357
M059J	GDSC1	4.4898	6.685	2.4852	2.3946
SF268	GDSC1	4.5009	7.6671	2.0358	4.6637
YKG-1	GDSC1; GDSC2	4.5443	7.3442	2.2153	3.6613
CAS-1	GDSC1	4.5851	6.3949	2.6666	1.4256
KNS-42	GDSC1; GDSC2	4.5989	7.4434	2.2032	3.6345
H4	GDSC1	4.6088	7.7978	2.044	4.4344
T98G	GDSC1	4.6459	7.3852	2.259	3.2796
8-MG-BA	GDSC1	4.6495	6.9767	2.4465	2.3566
D283 Med	GDSC1	4.745	6.664	2.6349	1.3853
SF539	GDSC1	4.783	7.2955	2.3801	2.4902
D-336MG	GDSC1; GDSC2	4.7859	7.9297	2.0937	4.4044
KNS-81-FD	GDSC1; GDSC2	4.8207	6.5615	2.7152	0.986
D-392MG	GDSC1	4.8346	6.9332	2.5666	1.5793
DK-MG	GDSC1	4.9024	10.159	1.1141	8.7283
U-251MG	GDSC1	4.9063	8.4219	1.9403	4.4735
SF295	GDSC1; GDSC2	4.9249	10.6749	0.8805	9.8725
U-118MG	GDSC1	4.9379	7.3627	2.4363	2.0336
KINGS-1	GDSC1	4.9495	7.5859	2.3449	2.4361
SF126	GDSC1; GDSC2	4.9616	6.9893	2.6073	1.2781
LNZTA3WT4	GDSC1	5.0003	7.0757	2.5905	1.3079
Hs 683	GDSC1; GDSC2	5.1144	6.6477	2.812	0.4566
D-247MG	GDSC1; GDSC2	5.1289	8.9357	1.8398	5.2295
42-MG-BA	GDSC1	5.1348	7.4746	2.491	1.5793
U-87MG ATCC	GDSC1	5.138	7.4853	2.488	1.5881
D-423MG	GDSC1; GDSC2	5.1569	8.5061	2.0523	3.5409
AM-38	GDSC1	5.1632	7.0849	2.664	0.8905
NMC-G1	GDSC1; GDSC2	5.1727	6.959	2.7177	0.7037
ONS-76	GDSC1	5.1974	7.7265	2.4164	1.8256
Becker	GDSC1	5.203	7.1847	2.6424	0.9356
KS-1 [Human Krukenberg tumour]	GDSC1	5.2254	7.7867	2.4053	1.8426
D-502MG	GDSC1; GDSC2	5.2621	7.6505	2.4809	1.4939
Onda 11	GDSC1; GDSC2	5.2627	7.2536	2.6421	0.8914
YH-13	GDSC1	5.2817	6.8986	2.7867	0.4394
SNB-75	GDSC1; GDSC2	5.2824	7.9295	2.374	1.9141
Daoy	GDSC1	5.2892	7.7903	2.4361	1.6484
MOG-G-CCM	GDSC1	5.3456	8.0443	2.3577	1.9154
D-566MG	GDSC1; GDSC2	5.5814	7.3439	2.7423	0.4128
LN-229	GDSC1	5.6117	7.4229	2.7253	0.4405
Onda 10	GDSC1; GDSC2	5.622	7.7423	2.6095	0.7542
MOG-G-UVW	GDSC1	5.7362	7.9021	2.597	0.7235
DBTRG-05MG	GDSC1	5.7596	7.3815	2.7968	0.2362
A-172	GDSC1	5.781	7.4502	2.7806	0.2593
SK-MG-1	GDSC1	6.005	7.8019	2.7398	0.2674
GI-1	GDSC1	6.0778	7.791	2.7702	0.1986
KALS-1	GDSC1	6.2043	8.1678	2.6849	0.3085
D-245MG	GDSC2	6.5881	9.3105	2.4195	0.8599
SW1088	GDSC1	6.6406	15.2442	-0.1522	11.5479

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TGBC24TKB	GDSC1	5.2322	7.9107	2.356	2.0464
TGBC1TKB	GDSC1	5.7251	7.2153	2.8421	0.1712
ETK-1	GDSC1	6.3041	8.362	2.6535	0.3367

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MFE-280	GDSC1	2.6823	4.9129	-0.7062	0.9014
KLE	GDSC1	4.6182	7.6266	2.1301	3.9756
AN3-CA	GDSC1	4.698	7.7512	2.122	3.8873
RL95-2	GDSC1	5.1261	7.0224	2.6719	1.2574
EN	GDSC1	5.1497	6.8512	2.7494	0.6188
MFE-319	GDSC1	5.3077	7.1697	2.6948	0.6883
ESS-1	GDSC1	5.5826	7.0312	2.8543	0.1864
MFE-296	GDSC1	5.7465	7.3852	2.7907	0.2511

Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KMRC-1	GDSC1	1.9708	3.517	-0.4756	0.5439
ACHN	GDSC1	4.205	6.387	2.448	3.0289
KTCTL-21	GDSC1; GDSC2	4.409	8.0726	1.7802	6.9951
BFTC-909	GDSC1	4.4401	6.6707	2.4622	2.5807
RCC10RGB	GDSC1	4.5581	6.5519	2.5836	1.8327
SW13	GDSC1	4.653	7.0243	2.4272	2.444
NCC010	GDSC1; GDSC2	4.6773	8.3446	1.8304	6.1344
VMRC-RCW	GDSC1; GDSC2	4.9013	7.3057	2.4413	2.0553
VMRC-RCZ	GDSC1	4.9708	6.7238	2.7199	0.8426
A-704	GDSC1	4.9895	6.8917	2.661	1.0432
SN12C	GDSC1	4.9902	7.1418	2.5579	1.4505
A-498	GDSC1	5.0477	6.6566	2.7805	0.5871
KTCTL-140	GDSC1; GDSC2	5.0918	8.4632	2.0336	4.2152
SW156	GDSC1; GDSC2	5.1071	8.3672	2.0859	3.4494
KMRC-20	GDSC1	5.1529	7.1762	2.6227	1.0469
KTCTL-26A	GDSC1; GDSC2	5.1529	6.9415	2.7158	0.8193
HA7-RCC	GDSC1; GDSC2	5.1743	7.9258	2.3189	2.2764
LB2241-RCC	GDSC1; GDSC2	5.1867	7.4404	2.5309	1.367
LB996-RCC	GDSC1	5.3369	7.8512	2.4344	1.6081
BB65-RCC	GDSC1; GDSC2	5.3396	7.2586	2.6742	0.7322
LB1047-RCC	GDSC1; GDSC2	5.3796	7.8946	2.4374	1.5545
RXF 393L	GDSC1; GDSC2	5.3825	7.895	2.4387	1.5467
769-P	GDSC1	5.452	7.3346	2.6931	0.6069
KTCTL-1M	GDSC1; GDSC2	5.475	7.2706	2.7267	0.5682
786-O	GDSC1	5.4769	7.3643	2.6923	0.5954
KTCTL-195	GDSC1	5.7547	7.5689	2.7282	0.5283
UO-31	GDSC1; GDSC2	5.8345	8.2501	2.5054	0.9435
OS-RC-2	GDSC1	5.8708	7.6578	2.7407	0.3071
NCC021	GDSC1; GDSC2	5.9366	7.8214	2.7073	0.399
Caki-1	GDSC1; GDSC2	5.9495	13.5307	0.2064	11.1758
CAL-54	GDSC1	5.9594	7.8746	2.6969	0.3657
KTCTL-13	GDSC1; GDSC2	6.1017	8.0272	2.6963	0.3611
TK-10	GDSC1	6.1553	8.1668	2.6669	0.3591

Cancer Drug Sensitivity Data Curated from 47 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HT-55	GDSC1	1.5494	3.2948	-0.5733	1.3744
HCT 15	GDSC1	1.8678	3.2195	-0.4076	0.3808
SW948	GDSC1	3.5067	8.9084	0.6812	14.0893
CaR-1	GDSC1	3.8084	6.8021	1.9688	6.4009
SNU-1040	GDSC1	4.2051	6.3383	2.4709	4.1051
SW1463	GDSC1	4.2179	6.8269	2.2481	4.054
SNU-C1	GDSC1	4.2321	6.5048	2.41	3.1796
HT115	GDSC1; GDSC2	4.3188	5.9428	2.7194	1.5111
SK-CO-1	GDSC1	4.5203	6.3424	2.6547	2.1942
SW1116	GDSC1	4.7306	9.1172	1.4976	9.7924
CL-11	GDSC1	4.7435	7.0408	2.4709	2.1168
SW1417	GDSC1	4.7716	6.8429	2.5723	1.6252
SNU-283	GDSC2	4.777	6.882	2.5583	1.9034
NCI-H716	GDSC1	4.7985	7.5807	2.2609	3.0422
COLO205	GDSC1	4.8165	6.5563	2.7153	0.9892
LS180	GDSC1	4.8256	11.3336	0.4896	12.0169
T84	GDSC1	4.8563	9.3305	1.4801	6.9255
HT-29	GDSC1; GDSC2	4.9322	6.3538	2.8472	0.4571
MDST8	GDSC1	4.997	6.6618	2.7563	0.6981
SW48	GDSC1	5.1111	6.7411	2.7752	0.5643
SW837	GDSC1	5.1237	7.4068	2.5138	1.497
LoVo	GDSC1	5.1436	7.2593	2.5845	1.198
NCI-H508	GDSC1; GDSC2	5.1516	7.4969	2.49	1.7737
SNU-407	GDSC1	5.1645	7.9017	2.324	3.1904
CCK-81	GDSC1	5.2213	7.3748	2.5744	1.1682
COLO 678	GDSC1	5.2378	7.1499	2.6719	0.8089
SNU-61	GDSC1	5.2776	7.7311	2.455	2.2315
SNU-C2B	GDSC1	5.3497	7.9953	2.3805	1.8158
COLO 320HSR	GDSC1	5.3501	7.7319	2.4902	1.3752
KM12	GDSC1	5.352	6.788	2.8545	0.2536
LS1034	GDSC1	5.3621	6.766	2.8661	0.2277
HCC2998	GDSC1	5.3781	7.3842	2.6423	0.8088
SNU-81	GDSC1; GDSC2	5.3845	7.6592	2.5361	1.3281
NCI-H747	GDSC1	5.3911	7.74	2.5064	1.2769
LS123	GDSC1	5.4072	7.3922	2.6519	0.7589
LS411N	GDSC1	5.4226	6.6376	2.9325	0.1085
HCT 116	GDSC1	5.5054	6.9903	2.8403	0.2321
GP5d	GDSC1	5.517	6.8671	2.8874	0.1508
RCM-1 [Human ESC]	GDSC1	5.5296	6.908	2.8779	0.1623
SW620	GDSC1; GDSC2	5.5309	7.5367	2.6495	0.689
SNU-C5	GDSC1	5.7107	7.4953	2.7378	0.5225
SW626	GDSC1	5.8275	7.8295	2.6617	0.5003
C2BBe1	GDSC1	5.8352	7.9803	2.6087	0.6351
LS513	GDSC1	5.8537	7.3404	2.8449	0.1405
RKO	GDSC1	5.8875	7.4674	2.8135	0.1772
CW-2	GDSC1	5.9169	7.8595	2.6859	0.4055
DiFi	GDSC1	6.7785	8.6519	2.7236	0.1833

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC1	5.0474	7.6476	2.3714	2.1931

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-475	GDSC1	1.8418	3.5825	-0.5543	0.9627
SNU-387	GDSC1	2.4325	4.5513	-0.6735	0.9626
JHH-6	GDSC1	3.7391	5.4932	2.5613	3.293
Hep 3B2.1-7	GDSC1; GDSC2	3.9509	6.1214	2.4054	3.7158
Hep-G2/C3A	GDSC1	4.1682	6.4308	2.4036	3.3239
JHH-7	GDSC1	4.3296	7.5169	1.9932	5.2015
SNU-423	GDSC1	4.6112	7.5616	2.156	3.8549
SNU-449	GDSC1	4.7844	6.9907	2.5152	1.8636
SK-HEP-1	GDSC1	4.8101	6.0854	2.8977	0.3815
Huh-7	GDSC1	5.0668	6.5975	2.8112	0.4846
SNU-398	GDSC1	5.2158	7.7935	2.3974	1.8865
JHH-1	GDSC1	5.3813	6.511	2.9609	0.0822
JHH-2	GDSC1	5.3936	7.2328	2.7072	0.5993
HuH-1	GDSC1	5.3999	6.7581	2.8828	0.1867
HLE	GDSC1	5.6854	7.7477	2.6342	0.6447
JHH-4	GDSC1	5.7812	9.3238	2.0379	2.8088

Cancer Drug Sensitivity Data Curated from 185 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H64	GDSC1	1.4703	2.8437	-0.4297	0.7483
NCI-H2228	GDSC1	1.6171	5.2541	-1.4041	6.6656
NCI-H1963	GDSC1	2.0326	3.8477	-0.5744	0.8805
NCI-H1650	GDSC1	2.2208	3.8804	-0.51	0.5083
NCI-H2795	GDSC1	2.2563	4.2705	-0.6409	0.9721
NCI-H647	GDSC1; GDSC2	3.5508	5.5812	2.3769	4.7232
NCI-H1299	GDSC1	3.8877	8.0283	1.422	9.2224
BEN	GDSC1; GDSC2	3.899	6.8856	1.9951	6.0582
SBC-3	GDSC1	3.9205	6.6974	2.1033	5.4193
EBC-1	GDSC1	3.9215	7.171	1.8713	6.6892
NCI-H1793	GDSC1	4.1892	7.0641	2.115	4.8175
Calu-6	GDSC1	4.2149	7.7742	1.789	6.5224
LXF 289	GDSC1	4.2174	5.9554	2.6555	1.9579
COR-L32	GDSC1; GDSC2	4.2306	6.55	2.3878	3.7352
HCC33	GDSC1; GDSC2	4.2489	5.7752	2.7545	1.4384
NCI-H82	GDSC1	4.3017	7.7326	1.8701	5.913
NCI-H2444	GDSC1; GDSC2	4.3214	6.3102	2.5557	2.2955
NCI-H1437	GDSC1; GDSC2	4.3346	7.2288	2.1343	4.4437
NCI-H146	GDSC1; GDSC2	4.4839	7.5614	2.0747	5.0835
NCI-H2122	GDSC1	4.5014	8.4751	1.6497	6.702
NCI-H661	GDSC1	4.5093	6.9623	2.3703	2.9329
NCI-H1770	GDSC1; GDSC2	4.5152	6.8654	2.4182	2.6859
NCI-H446	GDSC1	4.5232	6.9723	2.3741	2.8929
NCI-H187	GDSC1	4.524	6.3329	2.6608	1.5231
NCI-H1105	GDSC1; GDSC2	4.5249	7.7527	2.011	5.3776
NCI-H1573	GDSC1	4.5295	6.6656	2.5169	2.1852
NCI-H2804	GDSC1; GDSC2	4.5328	9.3807	1.2328	8.8441
NCI-H1341	GDSC1	4.5413	6.3591	2.6588	2.1325
NCI-H2227	GDSC1; GDSC2	4.5444	7.5926	2.0992	4.2586
UMC-11	GDSC1	4.5449	6.3415	2.6683	1.4648
CPC-N	GDSC1	4.5464	6.7894	2.471	2.3824
SK-LU-1	GDSC1	4.5508	7.7375	2.035	4.5806
NCI-H1581	GDSC1	4.5655	7.6372	2.0918	4.261
COR-L279	GDSC1	4.566	9.3902	1.2517	11.9304
IA-LM	GDSC1	4.5781	7.7602	2.042	4.4972
NCI-H720	GDSC1	4.5828	6.1513	2.7685	0.9982
NCI-H2087	GDSC1	4.5942	7.9136	1.9801	4.7909
EMC-BAC-2	GDSC1	4.6054	8.1235	1.8881	7.3568
NCI-H211	GDSC1	4.6178	7.9147	1.9948	4.6736
COR-L23	GDSC1	4.6179	6.6097	2.5911	1.7237
NCI-H1703	GDSC1	4.6214	8.1061	1.9068	5.1251
NCI-H209	GDSC1	4.6476	7.8218	2.0575	4.2994
SBC-5	GDSC1	4.6586	5.8998	2.9045	0.4489
KNS-62	GDSC1	4.6602	10.8813	0.5912	15.8627
NCI-H1836	GDSC1; GDSC2	4.6679	8.4225	1.7872	5.667
RERF-LC-MS	GDSC1; GDSC2	4.6704	7.0221	2.4381	2.368
NCI-H2066	GDSC1	4.6853	6.5676	2.6451	1.9843
NCI-H748	GDSC1; GDSC2	4.7069	7.7454	2.1302	3.8314
SK-MES-1	GDSC1	4.7114	7.6711	2.1673	3.6375
NCI-H1781	GDSC1	4.7131	7.1074	2.4243	2.3751
NCI-H1436	GDSC1; GDSC2	4.7185	6.636	2.6331	1.4215
LCLC-103H	GDSC1	4.7222	6.2981	2.7756	0.8432
NCI-H2029	GDSC1; GDSC2	4.7291	6.0466	2.8783	0.4854
NCI-H841	GDSC1	4.7309	6.8205	2.5604	1.7254
NCI-H345	GDSC1; GDSC2	4.7437	5.8976	2.9407	0.3005
NCI-H522	GDSC1	4.7465	7.4113	2.3071	2.8924
HCC15	GDSC1	4.77	7.3938	2.3287	2.7541
NCI-H2373	GDSC1	4.7829	7.047	2.4899	1.9802
NCI-H1651	GDSC1	4.7844	9.2788	1.4565	7.1811
NCI-H2135	GDSC1; GDSC2	4.7891	6.7854	2.606	1.4602
NCI-H1975	GDSC1	4.8147	7.2368	2.424	2.2426
NCI-H2818	GDSC1	4.8169	8.6452	1.7792	5.4461
NCI-H1755	GDSC1	4.8263	6.8384	2.6026	1.4347
NCI-H1435	GDSC1	4.8352	7.0568	2.5138	1.8095
NCI-H2369	GDSC1	4.8546	6.4332	2.7826	0.7125
NCI-H810	GDSC1	4.8568	6.8087	2.6305	1.2872
NCI-H835	GDSC1	4.8771	8.058	2.0902	5.2928
NCI-H2171	GDSC1; GDSC2	4.8779	6.3076	2.8418	0.5048
NCI-H69	GDSC1	4.8869	7.5155	2.341	2.5358
NCI-H2081	GDSC1; GDSC2	4.8869	7.1973	2.4806	1.8962
Calu-3	GDSC1	4.8923	7.2326	2.4682	1.9452
NCI-H3255	GDSC1; GDSC2	4.9134	8.6601	1.8339	5.002
NCI-H2110	GDSC1; GDSC2	4.9231	7.0881	2.5464	1.5692
NCI-H2141	GDSC1	4.9251	6.289	2.8686	0.4007
Lu-165	GDSC1	4.9682	6.6886	2.7328	0.7993
LOU-NH91	GDSC1	4.9695	6.8176	2.6816	0.983
NCI-H2030	GDSC1; GDSC2	4.9747	7.3879	2.445	1.951
IST-SL1	GDSC1; GDSC2	4.9779	7.4137	2.4356	1.9891
NCI-H2461	GDSC1	4.9834	7.1436	2.5537	1.4749
NCI-H1092	GDSC1	4.9848	6.9165	2.6486	1.0944
NCI-H510A	GDSC1; GDSC2	4.9865	6.7706	2.7085	0.871
NCI-H1693	GDSC1	4.9939	7.6706	2.3322	2.438
COR-L88	GDSC1	5.0024	6.9118	2.6589	1.0398
Lu-99A	GDSC1	5.0119	7.4557	2.4355	1.9501
A-549	GDSC1	5.0132	7.5426	2.3986	2.112
ChaGo-K-1	GDSC1; GDSC2	5.0318	7.8591	2.27	2.6775
NCI-H226	GDSC1	5.0345	6.3609	2.8861	0.3046
NCI-H23	GDSC1	5.038	7.1791	2.5661	1.3692
NCI-H1563	GDSC1	5.0415	7.0833	2.6075	1.2019
ABC-1	GDSC1; GDSC2	5.0555	8.8509	1.8339	4.7707
SW1573	GDSC1	5.0667	7.4136	2.482	1.6878
LB647-SCLC	GDSC1; GDSC2	5.0768	7.1121	2.6127	1.1497
NCI-H1688	GDSC1	5.0888	7.3122	2.5359	1.4415
NCI-H740	GDSC2	5.0985	10.2783	1.1897	8.963
DMS 114	GDSC1	5.1087	8.0344	2.2354	2.7385
DMS 53	GDSC1	5.1105	7.2124	2.5878	1.2151
NCI-H250	GDSC2	5.1118	9.5789	1.5297	7.0139
PC-14	GDSC1; GDSC2	5.1285	7.3637	2.5341	1.4099
COR-L105	GDSC1	5.131	7.7459	2.3735	2.0852
NCI-H2009	GDSC1	5.148	7.5178	2.4795	1.6132
DMS 79	GDSC1; GDSC2	5.1568	7.1674	2.6281	1.0239
NCI-H292	GDSC1; GDSC2	5.1619	7.2598	2.593	1.1496
NCI-H358	GDSC1	5.1683	7.1491	2.6407	0.9688
LC-2/ad	GDSC1; GDSC2	5.1719	7.4641	2.5139	1.449
Lu-65	GDSC1	5.1758	7.4405	2.5255	1.3988
NCI-H2342	GDSC1	5.1813	7.6263	2.4506	1.6989
NCI-H526	GDSC1	5.1816	6.4054	2.9261	0.172
NCI-H1568	GDSC1	5.2036	7.5621	2.4887	1.5193
NCI-H1048	GDSC1	5.2361	7.1543	2.6694	0.8185
NCI-H1355	GDSC1	5.2679	7.9804	2.3448	2.0551
NCI-H2405	GDSC1	5.2691	9.3461	1.7364	4.922
NCI-H196	GDSC1	5.2733	6.5801	2.8986	0.1945
NCI-H2803	GDSC1; GDSC2	5.2831	7.1438	2.6941	0.7061
EKVX	GDSC1; GDSC2	5.2961	8.5318	2.1201	3.0309
Lu-139	GDSC1	5.3315	7.8219	2.4439	1.5749
NCI-H1694	GDSC1	5.3344	7.0034	2.769	0.4597
Ms-1	GDSC1	5.3484	7.309	2.6585	0.7764
DMS 273	GDSC1	5.3527	7.3352	2.6502	0.8005
HOP-62	GDSC1	5.3527	6.8783	2.8223	0.3216
NCI-H847	GDSC1	5.3606	6.8973	2.8184	0.3271
NCI-H2810	GDSC2	5.3722	7.3939	2.6359	0.9447
NCI-H1869	GDSC1	5.3803	7.7647	2.4912	1.3439
NCI-H460	GDSC1; GDSC2	5.3854	6.7797	2.8699	0.2135
CAL-12T	GDSC1; GDSC2	5.3964	8.4928	2.1921	2.5778
RERF-LC-KJ	GDSC1	5.4172	7.0542	2.7835	0.385
VMRC-LCD	GDSC1	5.422	6.827	2.8668	0.294
A-427	GDSC1; GDSC2	5.4347	8.0383	2.4049	1.6315
RERF-LC-Sq1	GDSC1	5.4402	8.028	2.4119	1.5983
NCI-H1648	GDSC1	5.4557	8.0274	2.4197	1.5526
LK-2	GDSC1	5.4655	7.3069	2.7092	0.554
NCI-H2172	GDSC1; GDSC2	5.4684	7.1352	2.774	0.3856
NCI-H524	GDSC1	5.4698	7.2562	2.7299	0.4956
NCI-H1915	GDSC1	5.482	6.9453	2.8474	0.2259
COR-L95	GDSC1	5.4915	7.1361	2.7828	0.3556
SBC-1	GDSC1; GDSC2	5.5264	7.0737	2.8186	0.2669
NCI-H2196	GDSC1; GDSC2	5.5273	7.1861	2.7786	0.3509
IST-SL2	GDSC1; GDSC2	5.5294	8.7954	2.1321	2.687
NCI-H2591	GDSC1	5.5324	8.1108	2.4226	1.4711
NCI-H838	GDSC1; GDSC2	5.5383	6.9916	2.852	0.2019
NCI-H1155	GDSC1	5.5411	7.0257	2.8411	0.2201
NCI-H322M	GDSC1	5.5418	8.0364	2.4573	1.3314
COR-L321	GDSC1; GDSC2	5.5424	7.2313	2.768	0.4177
HOP-92	GDSC1	5.5482	8.3618	2.3265	1.8367
NCI-H1876	GDSC1	5.5556	7.3652	2.7241	0.4691
COLO 668	GDSC1	5.5604	7.5802	2.6454	0.6838
Lu-135	GDSC1	5.5691	7.6769	2.612	0.7797
EPLC-272H	GDSC1	5.5776	8.0672	2.4617	1.2853
COR-L303	GDSC2	5.5819	7.3362	2.7453	0.4591
NCI-H2722	GDSC1	5.5925	7.3266	2.753	0.383
NCI-H2170	GDSC1	5.6005	8.0672	2.4724	1.2276
LCLC-97TM1	GDSC1	5.6222	7.7755	2.5968	0.793
HCC366	GDSC1; GDSC2	5.6239	7.6707	2.6377	0.7582
NCI-H1993	GDSC1	5.631	7.4867	2.7095	0.4708
NCI-H290	GDSC1; GDSC2	5.6321	7.8229	2.5828	0.8305
SHP-77	GDSC1	5.6464	7.114	2.8487	0.1796
NCI-H2291	GDSC1; GDSC2	5.6677	7.9527	2.548	0.9183
NCI-H1838	GDSC1	5.6727	7.6855	2.6524	0.6008
NCI-H2085	GDSC1	5.6875	7.4653	2.7396	0.3752
NCI-H1304	GDSC1	5.7056	7.2328	2.829	0.1964
PaCa-3	GDSC1	5.7214	8.1742	2.4849	1.0901
NCI-H441	GDSC1	5.7239	8.4047	2.3939	1.4126
NCI-H727	GDSC1	5.7362	8.2622	2.4567	1.1765
NCI-H596	GDSC1	5.7641	7.3195	2.8201	0.196
NCI-H2595	GDSC1	5.8199	7.8871	2.6373	0.5662
NCI-H520	GDSC1	5.8316	7.7556	2.6904	0.4295
HARA [Human squamous cell lung carcinoma]	GDSC1	5.8334	7.4671	2.794	0.221
NCI-H3122	GDSC1	5.8614	8.1927	2.5391	0.8213
HCC44	GDSC1	5.8788	7.8374	2.6791	0.4362
HCC827	GDSC1	5.8938	7.5488	2.7875	0.216
NCI-H1666	GDSC1	5.8939	12.9575	0.4421	10.1889
NCI-H2347	GDSC1	5.9291	7.9335	2.6638	0.4509
NCI-H1734	GDSC1; GDSC2	5.9599	8.058	2.6303	0.5179
NCI-H650	GDSC1	6.0062	7.7532	2.7573	0.2368
Lu-134-A	GDSC1; GDSC2	6.0075	8.4554	2.5008	0.8484
NCI-H1944	GDSC1	6.0307	7.8209	2.7427	0.2551
HCC78	GDSC1	6.1795	7.9593	2.7487	0.2077
NCI-H513	GDSC1	6.1821	8.3822	2.5995	0.4957
SW1271	GDSC1	6.186	7.9542	2.7528	0.2001
NCI-H1792	GDSC1	6.233	8.0999	2.7193	0.2408
NCI-H2869	GDSC1; GDSC2	6.2399	8.3055	2.6495	0.3656
NCI-H1623	GDSC1	6.2706	8.4721	2.6014	0.4559
NCI-H2731	GDSC1	6.2788	8.163	2.714	0.2378
EMC-BAC-1	GDSC1; GDSC2	6.3565	9.0258	2.4309	0.9633
LC-1/sq	GDSC1	6.7826	9.0358	2.5937	0.3057
NCI-H2023	GDSC1	7.9816	17.5331	-0.3781	10.3686

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC1	5.5175	8.1216	2.4109	1.5296

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KYSE-410	GDSC1	2.574	4.9766	-0.776	1.2769
KYSE-140	GDSC1	2.886	4.6814	-0.5445	0.3068
KYSE-180	GDSC1	3.8558	5.737	2.5252	3.2556
OE21	GDSC1	4.0554	7.5651	1.7762	6.9219
TE-1	GDSC1	4.3633	6.6565	2.4219	2.9018
TE-4	GDSC1	4.4072	6.7703	2.3964	4.1758
TE-9	GDSC1	4.591	6.6027	2.5795	1.8101
TE-5	GDSC1	4.6736	7.2463	2.3389	2.8424
TE-15	GDSC1	4.7015	7.499	2.2404	3.2873
OE19	GDSC1	4.7093	6.2297	2.7972	0.7745
KYSE-510	GDSC1; GDSC2	4.8535	7.7683	2.2082	3.2196
KYSE-450	GDSC1	4.9431	6.8477	2.6568	1.1004
T.T	GDSC1	4.9617	7.3189	2.4679	1.8655
OE33	GDSC1	4.979	7.2327	2.5138	1.6476
EC-GI-10	GDSC1	5.0654	7.1918	2.5744	1.3097
KYSE-270	GDSC1	5.1828	8.1796	2.2125	2.749
TE-6	GDSC1	5.2036	7.4338	2.5418	1.3086
KYSE-70	GDSC1	5.4948	7.4437	2.6696	0.6507
COLO 680N	GDSC1	5.6555	7.3064	2.7845	0.2916
TE-8	GDSC1	5.6699	7.6915	2.6491	0.6115
TE-10	GDSC1; GDSC2	5.7562	7.8551	2.6231	0.6373
KYSE-150	GDSC1	5.7572	7.0566	2.9072	0.0846
TE-11	GDSC1; GDSC2	6.0673	7.7226	2.79	0.1722
KYSE-520	GDSC1	6.2104	8.4867	2.5724	0.5481

Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
OVKATE	GDSC1	2.4309	4.2867	-0.5756	0.6009
OAW42	GDSC1	4.083	5.9351	2.5821	2.5414
DOV13	GDSC1	4.26	9.5574	0.9472	14.8624
IGROV-1	GDSC1	4.3879	6.3637	2.5708	2.1242
EFO-27	GDSC1; GDSC2	4.3935	7.9676	1.8201	6.0031
OVCAR-5	GDSC1	4.4088	8.0138	1.8084	6.036
Caov-3	GDSC1; GDSC2	4.4373	8.0821	1.795	6.0527
OVTOKO	GDSC1	4.4407	6.6624	2.4663	2.5597
OVISE	GDSC1	4.4846	6.1244	2.7299	1.2634
OVK18	GDSC1; GDSC2	4.6619	10.3944	0.8307	11.9363
JHOS-4	GDSC1; GDSC2	4.6779	7.7156	2.1261	4.4143
OV-90	GDSC1	4.6866	6.8656	2.5166	1.9786
OV56	GDSC1	4.6965	6.3257	2.752	1.3488
TOV-112D	GDSC1	4.8252	9.8409	1.2143	8.3613
OVCAR-4	GDSC1	4.9271	7.267	2.4719	1.8875
A2780	GDSC1	4.9389	7.0513	2.57	1.4533
OC 314	GDSC1	4.9967	6.9729	2.6312	1.1505
JHOS-2	GDSC1; GDSC2	5.0165	6.9759	2.6395	1.247
SK-OV-3	GDSC1	5.0445	9.7556	1.4025	6.9853
EFO-21	GDSC1	5.0776	7.954	2.2536	2.6941
Caov-4	GDSC1	5.0817	7.6307	2.3971	2.0384
TOV-21G	GDSC1	5.0919	6.6312	2.8089	0.4774
RMG-I	GDSC1	5.1327	8.6197	1.9867	3.8945
OAW28	GDSC1	5.1448	8.0174	2.2629	2.5653
FU-OV-1	GDSC1	5.5329	7.5129	2.6594	0.6585
TYK-nu	GDSC1	5.5786	7.1476	2.812	0.2628
OVCAR-3	GDSC1	5.5792	7.4863	2.6887	0.5506
ES-2	GDSC1	5.8294	7.6742	2.719	0.3662
Kuramochi	GDSC1	5.9569	7.7006	2.7576	0.2496
OVCAR-8	GDSC1	6.6049	8.3439	2.7671	0.1099

Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HPAC	GDSC1	1.9505	3.4376	-0.4546	0.4844
DAN-G	GDSC1	2.1649	3.8968	-0.5381	0.6388
HuP-T3	GDSC1	2.45	4.2808	-0.566	0.5582
HuP-T4	GDSC1	2.5448	4.4257	-0.5816	0.5551
Capan-1	GDSC1	2.5841	4.17	-0.4765	0.2599
Panc 04.03	GDSC1	3.0342	4.5678	-0.4543	0.1178
PaTu 8988t	GDSC1	3.9404	6.6645	2.1339	5.2107
KP-4	GDSC1	4.4064	6.5016	2.5192	2.3497
KP-2	GDSC1	4.4093	11.4532	0.1231	14.6838
YAPC	GDSC1	4.425	7.0513	2.2768	3.5427
SU.86.86	GDSC1	4.6681	6.1668	2.8033	0.7862
Panc 08.13	GDSC1	4.6828	7.5328	2.2136	3.4497
HPAF-II	GDSC1	4.7908	6.9442	2.5388	1.7507
SW1990	GDSC1	4.7929	7.7097	2.1989	3.3549
PaTu 8902	GDSC1	4.8278	6.3688	2.796	0.6865
KP-1N	GDSC1	4.9316	7.4514	2.3941	2.232
Panc 03.27	GDSC1	4.9619	7.3697	2.4461	1.9614
QGP-1	GDSC1; GDSC2	4.9655	6.8361	2.6722	1.1574
Panc 10.05	GDSC1	5.0335	7.344	2.4945	1.6704
KP-3	GDSC1	5.1724	8.3283	2.1409	3.0972
AsPC-1	GDSC1	5.3258	8.0729	2.3354	2.0315
BxPC-3	GDSC1	5.3551	7.6147	2.5402	1.1817
MIA PaCa-2	GDSC1	5.364	6.9966	2.7835	0.4085
CFPAC-1	GDSC1	5.4872	7.348	2.7027	0.5604
PSN1	GDSC1	5.5779	7.3402	2.7422	0.4144
SUIT-2	GDSC1	5.6268	7.0252	2.8723	0.1488
Hs 766T	GDSC1	5.6954	7.3283	2.7917	0.2646
MZ-PC-1	GDSC1; GDSC2	5.7459	8.4434	2.3886	1.414
PL4	GDSC1	5.8688	7.8115	2.6846	0.4276
Capan-2	GDSC1	5.9102	7.8095	2.7014	0.3742
Panc 02.03	GDSC1	6.1319	7.7578	2.8008	0.1454

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MSTO-211H	GDSC1	2.301	4.3395	-0.6483	0.9659
IST-Mes1	GDSC1	2.4608	4.0092	-0.4654	0.2771
NCI-H2052	GDSC1	2.7113	4.4874	-0.5407	0.3617
NCI-H28	GDSC1	2.896	4.4839	-0.4736	0.1706
NCI-H2452	GDSC1	3.2694	5.9755	1.9511	7.7969
MPP 89	GDSC1	4.2748	9.1841	1.1421	9.8634

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PC-3	GDSC1	1.8618	5.2489	0.9766	17.3886
LNCaP clone FGC	GDSC1	3.6132	7.1475	1.6461	8.6353
NCI-H660	GDSC2	5.4432	6.788	2.8882	0.189
VCaP	GDSC1	5.4842	7.1306	2.7819	0.3606
DU145	GDSC1	5.6184	11.367	1.0144	7.9291
22Rv1	GDSC1	5.8861	7.9965	2.6235	0.5699

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-253	GDSC1	5.853	7.9419	2.6304	0.5681

Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A2058	GDSC1	1.3376	2.3339	-0.2927	0.3113
RPMI-7951	GDSC1	2.2159	3.6076	-0.4149	0.2488
IGR-1	GDSC1	2.2446	3.9212	-0.5155	0.5125
COLO 829	GDSC1	2.5784	4.2574	-0.509	0.3361
SK-MEL-28	GDSC1; GDSC2	3.7941	8.3458	1.1918	10.6855
UACC-257	GDSC1	4.0196	7.3707	1.8455	6.62
A101D	GDSC1	4.0306	6.0391	2.4988	3.0681
UACC-62	GDSC1	4.1193	6.9648	2.1146	4.955
GAK	GDSC1	4.2766	6.8969	2.2538	3.9185
SK-MEL-24	GDSC1	4.5085	10.2244	0.8027	11.123
WM793	GDSC1	4.5295	7.2405	2.2542	3.4869
SH-4	GDSC1	4.5717	7.7098	2.0616	4.4067
VMRC-MELG	GDSC1; GDSC2	4.581	7.3315	2.244	3.4563
Hs 938.T	GDSC1; GDSC2	4.6419	7.7716	2.0774	4.2067
SK-MEL-5	GDSC1; GDSC2	4.6521	6.3978	2.7001	1.2093
SK-MEL-30	GDSC1; GDSC2	4.6731	6.9042	2.4921	2.1096
A-431	GDSC1; GDSC2	4.6959	8.1331	1.9423	4.8112
SK-MEL-3	GDSC1; GDSC2	4.7313	6.7741	2.5807	1.635
HT-144	GDSC1	4.7439	8.3026	1.8935	4.9817
G-361	GDSC1	4.7682	6.8061	2.5863	1.5683
SK-MEL-2	GDSC1	4.8007	5.989	2.9298	0.3015
DJM-1	GDSC1; GDSC2	4.805	6.8455	2.5887	1.5171
COLO 679	GDSC1	4.8284	7.8116	2.1736	3.4267
LB373-MEL-D	GDSC1; GDSC2	4.8427	6.1485	2.8874	0.3925
WT2-iPS	GDSC1; GDSC2	4.8534	6.2605	2.8494	0.4967
IGR-37	GDSC1	4.8689	6.4769	2.7717	0.7394
LOX-IMVI	GDSC1	4.8839	7.5088	2.3423	2.5335
RVH-421	GDSC1; GDSC2	4.8874	11.6114	0.3983	12.3317
WM115	GDSC1	4.9651	6.1743	2.9267	0.2403
CP50-MEL-B	GDSC1; GDSC2	4.9655	7.7851	2.2655	2.7867
LB2518-MEL	GDSC1; GDSC2	5.0134	6.5614	2.8023	0.5417
MZ-MEL-2	GDSC1; GDSC2	5.0296	7.252	2.5314	1.5197
MMAc-SF	GDSC1; GDSC2	5.0522	7.5122	2.4325	1.9167
CP66-MEL	GDSC1; GDSC2	5.0907	6.3499	2.9118	0.2267
IST-MEL1	GDSC1	5.1307	7.3971	2.5213	1.4595
A-375	GDSC1; GDSC2	5.2179	7.2008	2.6428	0.9229
Hs 940.T	GDSC1; GDSC2	5.2598	7.1219	2.6925	0.7267
IPC-298	GDSC1; GDSC2	5.2606	7.0557	2.7184	0.645
A-388	GDSC1; GDSC2	5.2779	8.1886	2.2605	2.4138
CHL-1	GDSC1	5.3684	9.4113	1.7664	4.6227
Mel Ho	GDSC1; GDSC2	5.3883	7.0556	2.7714	0.4276
Mel JuSo	GDSC1	5.4164	7.0551	2.7828	0.3869
COLO 783	GDSC1; GDSC2	5.4448	7.0307	2.8028	0.329
COLO 792	GDSC1	5.4678	7.337	2.6988	0.5818
451Lu	GDSC1; GDSC2	5.5285	7.198	2.7747	0.3591
G-mel	GDSC1; GDSC2	5.5375	7.2131	2.7728	0.36
MZ-MEL-7	GDSC1; GDSC2	5.5641	7.0914	2.8264	0.2399
WM35	GDSC1	5.5662	8.1198	2.435	1.3939
SK-MEL-1	GDSC1	5.6777	6.9867	2.9033	0.1002
MeWo	GDSC1	5.7398	7.6077	2.7083	0.426
COLO 800	GDSC1; GDSC2	5.828	8.0031	2.5972	0.6711
M14	GDSC1	5.8491	7.7712	2.6916	0.4196
WM1552C	GDSC1	5.8518	7.8035	2.6808	0.4434
HMV-II	GDSC1	5.9036	7.9079	2.6631	0.4632
SK-MEL-31	GDSC1; GDSC2	5.9497	17.1778	-1.5569	19.8501
WM278	GDSC1	6.2146	8.2936	2.6441	0.3852
EquiPSC Line K2	GDSC1; GDSC2	5.0886	8.6524	1.9455	4.163

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC1; GDSC2	5.5013	8.436	2.2715	2.1134

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KYM-1	GDSC1	4.0061	6.3416	2.3373	3.9756
SK-LMS-1	GDSC1	4.0853	6.2336	2.4426	3.2664
EW-8	GDSC1	4.2799	8.0548	1.6985	6.8784
VA-ES-BJ	GDSC1	4.3277	7.1907	2.1479	4.3845
G-401	GDSC1	4.5283	7.4833	2.1402	4.0737
Hs 633.T	GDSC1	4.5602	6.7809	2.4829	2.3055
TE 441.T	GDSC1; GDSC2	4.5945	6.4416	2.6515	1.4813
Rh41	GDSC1	4.6381	6.3277	2.7225	1.1309
MES-SA	GDSC1	4.6425	6.0595	2.8346	0.6935
SW982	GDSC1	4.8438	6.9017	2.5847	1.4917
SW684	GDSC1	4.8556	6.1483	2.8928	0.3709
Rh18	GDSC1	4.8705	6.7212	2.6737	1.5539
MFH-ino	GDSC1	4.9632	7.3057	2.4744	1.8352
SW872	GDSC1	4.964	7.7074	2.2993	2.6296
Rh30	GDSC1	5.1051	7.5423	2.4472	1.7944
STS-0421	GDSC1; GDSC2	5.115	8.1885	2.1706	3.0342
RKN	GDSC1	5.1294	6.4901	2.8762	0.2885
A-204	GDSC1	5.3145	8.546	2.1241	2.9887
G-402	GDSC1	5.3591	9.5662	1.69	5.0127
GCT	GDSC1	5.3638	7.1931	2.7098	0.609
HT-1080	GDSC1	5.4842	7.0277	2.819	0.2802
SK-UT-1	GDSC1	5.8742	8.3944	2.4666	1.0425
RD	GDSC1	5.9261	8.0765	2.6099	0.5858

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
IM95	GDSC1	1.1529	3.2318	-0.7565	3.1615
GCIY	GDSC1	1.2933	3.659	-0.8675	3.6371
AGS	GDSC1	2.5226	3.9429	-0.4207	0.1702
MKN28	GDSC1	3.3626	5.6085	-0.6938	0.4829
ECC12	GDSC2	4.1251	6.4949	2.3445	4.2055
TMK-1	GDSC1; GDSC2	4.3932	6.3002	2.6024	1.9643
SCH	GDSC1; GDSC2	4.4892	6.8861	2.3931	2.8499
Fu97	GDSC1	4.5847	6.8789	2.453	2.4153
SNU-5	GDSC1	4.6087	6.6689	2.5601	1.877
RF-48	GDSC1	4.6509	6.5046	2.6541	1.4058
TGBC11TKB	GDSC1	4.7817	8.0669	2.0275	4.2319
MKN1	GDSC1	4.8932	7.0689	2.5391	1.6328
ECC10	GDSC1	4.9151	6.8198	2.6547	1.1342
HGC-27	GDSC1	4.9678	7.0405	2.5891	1.3455
NUGC-3	GDSC1	5.0243	7.1927	2.5536	1.4336
OCUM-1	GDSC1	5.0604	7.0263	2.6398	1.0613
SK-GT-2	GDSC1	5.1896	8.32	2.1543	4.233
HSC-39	GDSC1	5.2034	6.696	2.8301	0.366
SNU-16	GDSC1	5.2721	6.7504	2.8373	0.3198
Hs 746.T	GDSC1	5.2867	13.2616	-0.1209	17.9857
MKN45	GDSC1	5.3089	19.7564	-3.3038	24.9742
23132/87	GDSC1	5.371	7.0082	2.782	0.4091
RERF-GC-1B	GDSC1	5.6204	8.8343	2.1635	2.4449
NUGC-4	GDSC1	5.6432	7.3296	2.7715	0.3225
MKN7	GDSC1; GDSC2	5.6659	7.9917	2.5319	0.972
NCI-N87	GDSC1	5.9127	8.2543	2.5373	0.7959
SNU-1	GDSC1	5.9627	7.8616	2.7028	0.3523
SNG-M	GDSC1	5.2139	7.3673	2.574	1.176

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CGTH-W-1	GDSC1	2.2634	3.655	-0.4141	0.2311
8505C	GDSC1	2.5654	4.2613	-0.5152	0.3566
BHT-101	GDSC1	3.8344	5.7106	2.523	3.3092
K5	GDSC1	4.3705	8.9205	1.3411	8.606
HTC-C3	GDSC1	4.5384	7.0011	2.3701	2.8896
B-CPAP	GDSC1	4.612	7.2042	2.3215	3.0196
TT	GDSC1	4.7632	6.8882	2.5483	1.7409
8305C	GDSC1	4.8199	7.4804	2.3186	2.733
ML-1 [Human leukemia]	GDSC1; GDSC2	4.8701	6.8454	2.6219	1.3093
CAL-62	GDSC1	4.9832	6.7418	2.7184	0.8383
FTC-133	GDSC1	5.0178	7.1388	2.5729	1.3616
KMH-2	GDSC1; GDSC2	5.1469	7.5349	2.4717	1.6468
TT2609-C02	GDSC1	5.344	7.5028	2.5801	1.0461
WRO	GDSC1	5.5361	9.6012	1.7792	4.3163
IHH-4	GDSC1	5.5978	7.044	2.8554	0.1809
ASH-3	GDSC1	5.6078	6.9162	2.9028	0.1124

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
FaDu	GDSC1	2.0875	3.3249	-0.3634	0.1813
CAL-33	GDSC1	2.3938	4.2132	-0.5634	0.5823
DOK	GDSC1	3.2537	5.17	-0.5811	0.2685
HSC-3	GDSC1	3.3896	6.1372	1.9703	7.3818
HSC-4	GDSC1	3.8614	5.7342	2.5304	3.2163
CAL-27	GDSC1	4.0356	7.5021	1.7926	6.8745
OSC-20	GDSC1	4.0938	7.4911	1.8404	6.4922
KOSC-2	GDSC1; GDSC2	4.1112	6.3331	2.4124	3.3789
BICR 22	GDSC1	4.2598	6.626	2.3708	3.3357
HO-1-N-1	GDSC1	4.4525	7.0327	2.3028	3.3645
KON	GDSC1; GDSC2	4.5231	7.0246	2.3501	3.013
HSC-2	GDSC1	4.5438	7.0935	2.331	3.0768
BICR 31	GDSC1; GDSC2	4.6451	6.806	2.5198	2.0166
BICR 10	GDSC1	4.6939	6.7538	2.5695	1.7291
SCC-15	GDSC1	4.6992	7.1492	2.3977	2.5213
LB771-HNC	GDSC1	4.7134	7.3391	2.3203	2.8756
PCI-38	GDSC1	4.7336	6.9671	2.4979	2.0048
PE/CA-PJ15	GDSC1; GDSC2	4.7352	8.7398	1.6809	6.1008
PCI-15A	GDSC1; GDSC2	4.7565	6.4106	2.7461	0.9248
HO-1-u-1	GDSC1	4.881	6.9815	2.57	1.5141
BB30-HNC	GDSC1; GDSC2	4.9002	7.0515	2.5502	1.5777
SCC-9	GDSC1	4.9537	6.9871	2.6043	1.2976
JHU-022	GDSC1	4.9597	9.2582	1.5825	6.2115
BHY	GDSC1; GDSC2	5.0272	8.8824	1.8017	4.9789
SCC-4	GDSC1	5.0867	7.2185	2.5738	1.2919
BB49-HNC	GDSC1	5.1135	10.0391	1.3134	7.317
OSC-19	GDSC1; GDSC2	5.2006	6.8855	2.758	0.5624
Detroit 562	GDSC1	5.2433	7.2841	2.6212	0.9792
SCC-25	GDSC1; GDSC2	5.2599	12.3559	0.3004	12.0436
SAS	GDSC1	5.6032	7.75	2.5985	0.7999
SAT [Human HNSCC]	GDSC1	5.6183	9.0257	2.08	2.8136
JHU-029	GDSC1; GDSC2	5.6306	7.9577	2.5296	1.0049
Ca9-22	GDSC1	5.6321	8.0499	2.4938	1.1267
UPCI-SCC-090	GDSC1	5.717	7.6089	2.6988	0.4585
SKN-3	GDSC1	5.7518	7.4013	2.787	0.2563
BICR 78	GDSC1	5.7703	7.9206	2.6043	0.6827
PCI-06A	GDSC1; GDSC2	5.7784	8.0468	2.5596	0.8101
PCI-04B	GDSC1; GDSC2	5.8606	7.9558	2.6283	0.5698
PCI-30	GDSC1	5.9331	7.5081	2.8158	0.1641
NCI-H3118	GDSC1	6.0953	8.4731	2.5309	0.712
JHU-011	GDSC1; GDSC2	6.0985	8.3421	2.581	0.5776

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KU-19-19	GDSC1	1.7162	7.7279	-0.3295	24.2485
SW780	GDSC1	3.5553	8.9244	0.7127	13.8032
HT-1197	GDSC1	4.0364	6.301	2.3776	3.702
UM-UC-3	GDSC1	4.2608	7.8576	1.7809	6.4735
BFTC-905	GDSC1	4.4057	6.4324	2.5502	2.199
HT-1376	GDSC1	4.665	7.428	2.2509	3.2903
639V	GDSC1	4.7147	5.8535	2.9453	0.3023
CAL-29	GDSC1	4.917	6.6503	2.7246	0.8688
J82	GDSC1	5.215	7.2534	2.6205	1.0041
TCCSUP	GDSC1	5.3042	14.7025	-0.8127	16.8276
647V	GDSC1	5.4101	6.8836	2.8423	0.2583
SW1710	GDSC1	5.4923	7.2397	2.7452	0.4455
RT-112	GDSC1	5.5198	6.9204	2.87	0.1769
RT-4	GDSC1	5.8183	7.5443	2.7612	0.2841
5637	GDSC1	5.8625	8.1819	2.5437	0.8068
T24	GDSC1; GDSC2	6.0221	7.9323	2.7001	0.3374

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PA-1	GDSC1	1.6863	3.4755	-0.5821	1.2575
NCC-IT	GDSC1	2.0995	3.9126	-0.5708	0.8115
NEC8	GDSC1	2.1891	3.4913	-0.3843	0.1927
C-4-I	GDSC1	2.2923	3.6963	-0.418	0.2298
DoTc2 4510	GDSC1	2.4324	4.388	-0.6123	0.7274
NT2-D1	GDSC1	3.6402	5.7181	2.3777	4.5152
SiHa	GDSC1	4.1108	5.8178	2.6541	2.1276
C-33 A	GDSC1	4.1461	7.255	1.9928	5.5595
HeLa	GDSC1	4.1962	5.2059	2.9704	0.566
OVCA420	GDSC1	4.2494	9.355	1.0391	14.2947
JEG-3	GDSC1; GDSC2	4.2767	7.6274	1.9036	5.7823
SiSo	GDSC1	4.3411	7.2875	2.1107	4.5564
ACC-OV7	GDSC1; GDSC2	4.5412	8.0191	1.8953	6.0287
BPH-1	GDSC1	4.5454	7.3906	2.1944	3.7665
SW962	GDSC1; GDSC2	4.5497	6.7701	2.4817	2.326
SKG-IIIa	GDSC1	4.5577	7.6687	2.0719	4.3768
TC-YIK	GDSC1	4.5681	10.3315	0.7937	14.903
ME-180	GDSC1	4.8477	7.6601	2.2538	3.006
JAR	GDSC1; GDSC2	4.9576	6.7576	2.7003	0.9242
SKN	GDSC1	4.9616	7.6538	2.3216	2.5284
HEY	GDSC1	5.137	7.9858	2.2725	3.5642
PWR-1E	GDSC1	5.1425	7.077	2.6577	1.3105
Ca Ski	GDSC1	5.1546	7.8695	2.3327	2.2382
HT-3	GDSC1	5.1853	12.0474	0.3976	11.73
OVMIU	GDSC1	5.254	8.7128	2.0155	3.5811
HEC-1	GDSC1	5.2824	6.7247	2.8506	0.2863
OV17R	GDSC1; GDSC2	5.2931	7.6439	2.4988	1.579
SW954	GDSC1; GDSC2	5.3083	7.1739	2.6934	0.6921
SW756	GDSC1	5.3847	7.0341	2.7779	0.4129
OMC-1 [Human cervical carcinoma]	GDSC1; GDSC2	5.5619	7.5336	2.6637	0.6294
KGN	GDSC1	5.5837	8.6222	2.2348	2.1804
MS751	GDSC1	5.5934	7.3734	2.7363	0.422
LB831-BLC	GDSC1	5.6582	7.8476	2.5846	0.8082
PEO1	GDSC1	5.8366	8.07	2.5754	1.0273
CAL-39	GDSC1	5.8811	7.7795	2.701	0.3859
DSH1	GDSC1	6.0435	7.7494	2.7722	0.2035
OVCA433	GDSC1; GDSC2	6.0449	8.0413	2.6697	0.4444
JHOS-3	GDSC1; GDSC2	6.065	8.1694	2.6311	0.5332
UWB1.289	GDSC1; GDSC2	6.9959	9.1181	2.6417	0.2136

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Bicalutamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[13]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[14]
Midostaurin	DMI6E0R	Moderate	Decreased metabolism of Bicalutamide caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Idarubicin.	Acute myeloid leukaemia [2A60]	[16]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[16]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Oliceridine.	Acute pain [MG31]	[16]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Ivabradine.	Angina pectoris [BA40]	[16]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Bepridil.	Angina pectoris [BA40]	[17]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Dronedarone.	Angina pectoris [BA40]	[17]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[18]
Cilostazol	DMZMSCT	Moderate	Decreased metabolism of Bicalutamide caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[19]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Posaconazole.	Aspergillosis [1F20]	[16]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Levalbuterol.	Asthma [CA23]	[20]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Pirbuterol.	Asthma [CA23]	[21]
Budesonide	DMJIBAW	Moderate	Decreased metabolism of Bicalutamide caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[22]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[16]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[16]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[16]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Retigabine.	Behcet disease [4A62]	[16]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Bicalutamide caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[16]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Bicalutamide and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[24]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Eribulin.	Breast cancer [2C60-2C6Y]	[16]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Bicalutamide caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[25]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Bosutinib.	Breast cancer [2C60-2C6Y]	[16]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[16]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[21]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Halothane.	Corneal disease [9A76-9A78]	[16]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Probucol.	Coronary atherosclerosis [BA80]	[16]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Pasireotide.	Cushing syndrome [5A70]	[17]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Osilodrostat.	Cushing syndrome [5A70]	[16]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Bicalutamide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[26]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Clomipramine.	Depression [6A70-6A7Z]	[16]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Doxepin.	Depression [6A70-6A7Z]	[16]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Bicalutamide caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[27]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[16]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Deutetrabenazine.	Dystonic disorder [8A02]	[16]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Ingrezza.	Dystonic disorder [8A02]	[16]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Bicalutamide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Cannabidiol.	Epileptic encephalopathy [8A62]	[16]
Solifenacin	DMG592Q	Moderate	Decreased metabolism of Bicalutamide caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[28]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Bicalutamide caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[29]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Bicalutamide caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[13]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[16]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Bicalutamide caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[16]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[30]
MK-1439	DM215WE	Minor	Decreased metabolism of Bicalutamide caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Maraviroc	DMTL94F	Moderate	Decreased metabolism of Bicalutamide caused by Maraviroc mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Bicalutamide and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[34]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Bicalutamide and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[17]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Bicalutamide caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[35]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Bicalutamide caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[36]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Bicalutamide caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[13]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Bicalutamide caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[37]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of Bicalutamide caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[38]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[16]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[17]
Naloxegol	DML0B41	Minor	Decreased metabolism of Bicalutamide caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[39]
Pemigatinib	DM819JF	Moderate	Decreased metabolism of Bicalutamide caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[16]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Crizotinib.	Lung cancer [2C25]	[40]
Brigatinib	DM7W94S	Moderate	Decreased metabolism of Bicalutamide caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Ceritinib.	Lung cancer [2C25]	[17]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Bicalutamide caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[41]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of Bicalutamide caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[42]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Osimertinib.	Lung cancer [2C25]	[43]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Bicalutamide caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[44]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Selpercatinib.	Lung cancer [2C25]	[16]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Lumefantrine.	Malaria [1F40-1F45]	[13]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Halofantrine.	Malaria [1F40-1F45]	[45]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Hydroxychloroquine.	Malaria [1F40-1F45]	[16]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[16]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[46]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Idelalisib.	Mature B-cell leukaemia [2A82]	[47]
GDC-0199	DMH0QKA	Moderate	Decreased metabolism of Bicalutamide caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[13]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[48]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of Bicalutamide caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[49]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Vemurafenib.	Melanoma [2C30]	[17]
Selumetinib	DMC7W6R	Moderate	Decreased metabolism of Bicalutamide caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[50]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and LGX818.	Melanoma [2C30]	[16]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Bicalutamide caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[51]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Bicalutamide caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[52]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Siponimod.	Multiple sclerosis [8A40]	[13]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Fingolimod.	Multiple sclerosis [8A40]	[17]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Bicalutamide and Ozanimod.	Multiple sclerosis [8A40]	[53]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Romidepsin.	Mycosis fungoides [2B01]	[16]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[17]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Bicalutamide caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[16]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[16]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Bicalutamide caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[54]
Levomethadyl Acetate	DM06HG5	Major	Decreased metabolism of Bicalutamide caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[55]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Lofexidine.	Opioid use disorder [6C43]	[16]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Rucaparib.	Ovarian cancer [2C73]	[16]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Triclabendazole.	Parasitic worm infestation [1F90]	[16]
Pimavanserin	DMR7IVC	Moderate	Decreased metabolism of Bicalutamide caused by Pimavanserin mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[56]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[57]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Lefamulin.	Pneumonia [CA40]	[58]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Bicalutamide caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[59]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Bicalutamide caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[60]
Silodosin	DMJSBT6	Moderate	Decreased metabolism of Bicalutamide caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[61]
Everolimus	DM8X2EH	Moderate	Decreased metabolism of Bicalutamide caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[62]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Bicalutamide caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[16]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Bicalutamide caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[63]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Bicalutamide caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[13]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Iloperidone.	Schizophrenia [6A20]	[17]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Paliperidone.	Schizophrenia [6A20]	[16]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Amisulpride.	Schizophrenia [6A20]	[64]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Asenapine.	Schizophrenia [6A20]	[16]
LDE225	DMM9F25	Moderate	Decreased metabolism of Bicalutamide caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[65]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Bicalutamide caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
Docetaxel	DMDI269	Moderate	Decreased metabolism of Bicalutamide caused by Docetaxel mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[66]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Bicalutamide and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[16]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[17]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[17]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Bicalutamide caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[67]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Pitolisant.	Somnolence [MG42]	[16]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[16]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Bicalutamide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[68]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Lenvatinib.	Thyroid cancer [2D10]	[16]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Bicalutamide and Cabozantinib.	Thyroid cancer [2D10]	[16]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Bicalutamide caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[16]
Elagolix	DMB2C0E	Moderate	Decreased metabolism of Bicalutamide caused by Elagolix mediated inhibition of CYP450 enzyme.	Uterine fibroid [2E86]	[69]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[16]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[16]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Bicalutamide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[16]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 300	E00651	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Bicalutamide 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2863).
• [2] Bicalutamide FDA Label
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
• [7] Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
• [8] Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78.
• [9] Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen. Cancer Genet Cytogenet. 2006 Apr 15;166(2):130-8. doi: 10.1016/j.cancergencyto.2005.09.012.
• [10] Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol. 2005 Jan;57(1):83-92.
• [11] Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
• [12] Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.
• [13] Cerner Multum, Inc. "Australian Product Information.".
• [14] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [15] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
• [16] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [17] Canadian Pharmacists Association.
• [18] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [19] Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
• [20] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [21] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [22] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
• [23] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [24] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [25] Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
• [26] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [27] Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
• [28] Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
• [29] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [30] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [31] Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
• [32] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [33] Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [34] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [35] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [36] Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
• [37] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [38] Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
• [39] Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [40] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [41] Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
• [42] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [43] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [44] Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
• [45] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [46] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [47] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [48] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [49] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [50] Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [51] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [52] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [53] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [54] Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
• [55] Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
• [56] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [57] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [58] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [59] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
• [60] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [61] Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
• [62] Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
• [63] Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [64] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [65] Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
• [66] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
• [67] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
• [68] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [69] Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.